Definition

An orally bioavailable inhibitor of the receptor for advanced glycation end-products (RAGE), with potential antineoplastic activity. Upon oral administration, azeliragon targets and binds to RAGE, thereby preventing binding of RAGE ligands to RAGE, and prevents RAGE-mediated signaling, This may inhibit proliferation and induce apoptosis of tumor cells in which the RAGE pathway is overactivated. RAGE, a receptor belonging to the immunoglobulin superfamily, plays a key role in inflammation and is overexpressed in a variety of cancers. It plays a key role in tumor cell proliferation, survival and metastasis.